BiotechTube
Coherus Oncology

Coherus Oncology

Redwood City, United States· Est.
coherus.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $315M

Overview

Coherus Oncology is dedicated to extending patient survival through a portfolio of innovative immuno-oncology (I-O) combination therapies. The company has successfully commercialized LOQTORZI® and is advancing multiple clinical-stage candidates, including tagmokitug (anti-CCR8) and casdozokitug (IL-27 antagonist), across various solid tumors. With a leadership team of seasoned industry veterans and a strategic focus on novel I-O mechanisms, Coherus aims to transform cancer treatment by addressing key resistance pathways in the tumor microenvironment.

Oncology

Technology Platform

Focus on developing monoclonal antibody therapies targeting immuno-oncology pathways, with a strategic emphasis on combination therapies that pair an anti-PD-1 backbone with novel mechanisms to overcome resistance in the tumor microenvironment.

Funding History

4
Total raised:$315M
PIPE$150M
IPO$75M
Series B$55M
Series A$35M

Opportunities

Significant growth opportunities exist in expanding LOQTORZI into new indications and advancing novel combinations like tagmokitug and casdozokitug into larger solid tumor markets such as colorectal cancer and hepatocellular carcinoma.
Positive clinical data could also make Coherus an attractive partner or acquisition target for larger pharmaceutical companies seeking to bolster their immuno-oncology portfolios.

Risk Factors

Key risks include clinical trial failures for lead pipeline candidates, intense competition from larger pharmaceutical companies with greater resources, potential challenges in commercial execution as a mid-sized biotech, and the ongoing need for capital to fund late-stage development, which could lead to shareholder dilution.

Competitive Landscape

Coherus competes in the crowded immuno-oncology space dominated by Merck, Bristol Myers Squibb, and Roche. Its differentiation lies in focusing on niche indications (e.g., NPC) with its approved therapy and developing next-generation combinations targeting novel pathways like CCR8 and IL-27, which are not yet addressed by market leaders.

More companies in Biologics / Biosimilars →More companies in United States →